Aromatase inhibitor-induced bone loss increases the progression of estrogen receptor-negative breast cancer in bone and exacerbates muscle weakness in vivo

Aromatase inhibitors (AIs) cause muscle weakness, bone loss, and joint pain in up to half of cancer patients. Preclinical studies have demonstrated that increased osteoclastic bone resorption can impair muscle contractility and prime the bone microenvironment to accelerate metastatic growth. We hypo...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Oncotarget
Huvudupphovsmän: Wright, Laura E., Harhash, Ahmed A., Kozlow, Wende M., Waning, David L., Regan, Jenna N., She, Yun, John, Sutha K., Murthy, Sreemala, Niewolna, Maryla, Marks, Andrew R., Mohammad, Khalid S., Guise, Theresa A.
Materialtyp: Artigo
Språk:Inglês
Publicerad: Impact Journals LLC 2016
Ämnen:
Research Paper
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC5352410/
https://ncbi.nlm.nih.gov/pubmed/28039445
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.14139
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk